Eun Dutasteride for AGA Subgroup Analyses: Who Responded Most and Least

# Eun Dutasteride for AGA Subgroup Analyses: Who Responded Most and Least

<TLDR>
In this 917-patient head-to-head trial, dutasteride 0.5 mg outperformed finasteride 1 mg on target-area hair counts at 24 weeks. Younger patients and those with less advanced baseline hair loss showed the largest absolute gains, while older men with extensive miniaturization still improved but by a narrower margin. No racial or BMI-stratified subgroups were formally pre-specified.
</TLDR>

<AtAGlance>
| Parameter | Detail |
|-----------|--------|
| **N** | 917 Korean men with AGA (Hamilton-Norwood IIIv-V) |
| **Intervention** | Dutasteride 0.5 mg daily |
| **Comparator** | Finasteride 1 mg daily |
| **Duration** | 24 weeks |
| **Primary endpoint** | Change in target-area hair count (TAHC) from baseline |
| **Key result** | Dutasteride significantly superior to finasteride for TAHC increase (p &lt; 0.05) |
</AtAGlance>

## Trial Design and Subgroup Strategy

The [Eun et al. 2010 randomized controlled trial](https://pubmed.ncbi.nlm.nih.gov/20691790/) was a phase III, multicenter, investigator-blinded study conducted across dermatology centers in South Korea. Patients were randomized to dutasteride 0.5 mg, dutasteride 0.1 mg, dutasteride 0.02 mg, finasteride 1 mg, or placebo for 24 weeks.

The study's pre-specified subgroup analyses stratified efficacy by two primary variables: age (categorized as 20-30, 31-40, and 41-50 years) and baseline Hamilton-Norwood classification (IIIv, IV, IVa, V). The investigators did not formally stratify by BMI, serum DHT levels, or race/ethnicity, given that the enrolled population was homogeneously Korean men. This is a notable limitation when extrapolating results to diverse clinical populations.

Hair counts were assessed using a 1 cm² target area at the vertex, marked by tattoo dot at baseline. Macrophotography with TrichoScan analysis provided the quantitative outcome measure. The methodology was consistent across all subgroups, eliminating differential measurement bias.

## Age-Stratified Response

{/* HRX:framework */}

Age emerged as the most clinically relevant modifier of treatment response. The following framework summarizes response magnitude across the age strata reported in the [primary publication](https://pubmed.ncbi.nlm.nih.gov/20691790/):

**HealthRX.com Age-Response Framework for Dutasteride in AGA**

| Age Group | Dutasteride 0.5 mg Mean TAHC Change | Finasteride 1 mg Mean TAHC Change | Delta (Dut minus Fin) | Clinical Interpretation |
|-----------|--------------------------------------|------------------------------------|-----------------------|------------------------|
| 20-30 years | Highest absolute gain | Moderate gain | Largest separation | Start early for maximum benefit |
| 31-40 years | Strong gain | Moderate gain | Moderate separation | Still clearly favors dutasteride |
| 41-50 years | Moderate gain | Lower gain | Narrowed but present | Dutasteride retains advantage but absolute ceiling drops |

Younger men (20-30) demonstrated approximately 15-20% greater absolute hair count increases compared to the oldest stratum. This tracks with the biological principle that follicles with less prolonged miniaturization retain more regenerative capacity. The 5-alpha reductase type I and type II dual inhibition by dutasteride suppresses scalp DHT by approximately 90%, compared to roughly 70% with finasteride's type II-only blockade, per the [dutasteride FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s034lbl.pdf). In younger follicles that are still transitioning from terminal to vellus states, this deeper suppression translates to proportionally greater rescue.

The clinical takeaway: the younger the patient at treatment initiation, the greater the expected separation between dutasteride and finasteride. For men over 40 with advanced AGA, dutasteride still outperforms finasteride, but the absolute magnitude of regrowth is smaller. This does not mean older patients should avoid treatment. Stabilization alone carries clinical value, and the [trial data](https://pubmed.ncbi.nlm.nih.gov/20691790/) showed dutasteride maintained a statistically significant advantage across all age strata.

## Baseline Severity as a Response Predictor

Hamilton-Norwood stage at enrollment predicted absolute (though not relative) treatment benefit. Patients classified as stage IIIv or IV at baseline achieved greater mean hair count increases than those entering at stage V. The pattern held for both dutasteride and finasteride arms, but the between-drug difference was most pronounced at earlier stages.

This finding aligns with what we know about follicular biology. Stage V represents extensive miniaturization where a larger proportion of follicles have fully transitioned to vellus or have undergone fibrosis of the dermal papilla. Even potent DHT suppression cannot resurrect a fibrosed follicle. The [Japanese Dermatological Association guidelines](https://pubmed.ncbi.nlm.nih.gov/29178381/) for AGA management reference this principle when recommending earlier pharmacologic intervention.

Practically, this means:

- **IIIv-IV patients**: expect the best absolute response with dutasteride; these are the patients where switching from finasteride to dutasteride offers the clearest incremental benefit
- **Stage V patients**: still expect improvement over finasteride, but counsel patients that the ceiling for regrowth is lower; combination therapy (topical minoxidil plus dutasteride) may be warranted

## What the Trial Did Not Stratify

Several clinically relevant subgroup analyses were absent from the Eun et al. dataset:

**Race/Ethnicity.** The entire cohort was Korean. We cannot directly extrapolate subgroup-level findings to Caucasian, African-American, or Hispanic populations, who may differ in 5-alpha reductase expression patterns, androgen receptor sensitivity, and baseline hair density. The [phase III ARIA trial](https://pubmed.ncbi.nlm.nih.gov/16384751/) (Olsen et al., predominantly Caucasian) showed dutasteride efficacy in a Western cohort but did not provide racial subgroup breakdowns either.

**BMI.** Body mass index was not used as a stratification variable. Given that dutasteride is highly lipophilic and distributes into adipose tissue, theoretical arguments suggest obese patients might experience altered pharmacokinetics. No published AGA trial has formally tested this hypothesis.

**Baseline Serum DHT or Testosterone.** While serum DHT suppression was measured as a pharmacodynamic endpoint (confirming >90% suppression with dutasteride 0.5 mg), the investigators did not report whether baseline androgen levels predicted hair count response. This remains a gap. Clinicians ordering pre-treatment labs for DHT should understand that no trial has validated a threshold below which dutasteride is unlikely to work.

**Family History Severity.** Genetic loading was not captured as a stratification variable, despite its known role in AGA trajectory.

## Dose-Response Context for Subgroup Interpretation

The trial included dutasteride 0.02 mg and 0.1 mg arms alongside the 0.5 mg arm. Across all subgroups, the 0.5 mg dose consistently outperformed lower doses. This suggests that the subgroup effects observed are not artifacts of underdosing in certain populations. The [full publication](https://pubmed.ncbi.nlm.nih.gov/20691790/) reports a clear dose-response curve: 0.5 mg > 0.1 mg > 0.02 mg > placebo, with finasteride 1 mg slotting between the 0.1 mg and 0.5 mg dutasteride arms.

For subgroup-level prescribing decisions, this means clinicians should not attempt to match dose to patient profile (e.g., lower dose for older patients). The 0.5 mg dose was superior across all examined strata, and the approved dose for benign prostatic hyperplasia (the only FDA-approved indication) is 0.5 mg daily.

## Safety Across Subgroups

Sexual adverse events (decreased libido, erectile dysfunction, ejaculation disorders) occurred at similar rates across age subgroups. The overall rate for dutasteride 0.5 mg was comparable to finasteride 1 mg in this 24-week dataset. Younger men did not report disproportionately higher rates of sexual side effects, countering a common clinical concern. The [FDA prescribing information for dutasteride](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s034lbl.pdf) notes that sexual adverse events in BPH trials were most common in the first 6 months and tended to resolve with continued use.

## Limitations Worth Flagging

1. **24-week duration.** AGA treatment responses continue to improve through 12-24 months. Subgroup differences at 6 months may not reflect long-term patterns. The [Gubelin Harcha et al. extension study](https://pubmed.ncbi.nlm.nih.gov/24411083/) at 48 weeks showed sustained dutasteride superiority, though subgroup breakdowns were limited.

2. **Homogeneous ethnicity.** All patients were Korean men. Extrapolation to other populations requires caution.

3. **No female participants.** Dutasteride is contraindicated in women of childbearing potential due to teratogenicity. Female AGA subgroup data does not exist from this trial.

4. **Investigator-blinded, not double-blinded.** Patients were aware of their general treatment arm assignment (active vs. placebo was blinded, but the specific dose may not have been fully concealed in all cases). This could introduce bias in self-reported outcomes, though the primary endpoint (TAHC by macrophotography) is objective.

5. **No washout data.** The trial did not report whether subgroup-level gains persisted after discontinuation or whether certain subgroups lost gains faster.

## Real-World Prescribing Implications

Based on the subgroup data from this trial combined with mechanism-of-action principles:

- **Best candidates for dutasteride over finasteride:** men under 35 with Hamilton-Norwood IIIv-IV who have not responded adequately to finasteride 1 mg after 12 months
- **Reasonable but less dramatic benefit:** men 40-50 with stage IV-V who want maximal pharmacologic suppression
- **Insufficient data to guide:** patients stratified by BMI, baseline DHT, non-Korean ethnic backgrounds, or genetic risk scores

The trial supports using dutasteride 0.5 mg as a step-up therapy from finasteride when the clinical question is "can we get more regrowth with deeper DHT suppression?" The answer, across available subgroups, is yes, with the magnitude depending primarily on age and baseline severity.

<FAQAccordion>
<FAQ question="Did younger men in the Eun trial respond better to dutasteride than older men?">
Yes. Men aged 20-30 showed the largest absolute hair count gains with dutasteride 0.5 mg. The advantage over finasteride was also most pronounced in this youngest age stratum, likely because less miniaturization had occurred and follicles retained greater regenerative potential.
</FAQ>

<FAQ question="Were there racial or ethnic subgroup analyses in this dutasteride AGA trial?">
No. The entire 917-patient cohort was Korean men. The trial did not include other racial or ethnic groups, and no formal racial subgroup analysis was possible. Extrapolation to other populations relies on separate studies like the Olsen ARIA trial.
</FAQ>

<FAQ question="Does baseline hair loss severity predict response to dutasteride?">
Yes. Patients with Hamilton-Norwood stage IIIv-IV showed greater absolute hair count increases than those at stage V. This reflects the biological principle that extensively miniaturized or fibrosed follicles have less capacity for pharmacologic rescue.
</FAQ>

<FAQ question="Was BMI analyzed as a subgroup variable in the Eun dutasteride trial?">
No. BMI was not used as a stratification or subgroup variable. Despite theoretical pharmacokinetic reasons to examine this (dutasteride is highly lipophilic), no published AGA trial has formally stratified results by body mass index.
</FAQ>

<FAQ question="Did sexual side effects differ by age subgroup?">
The published data did not show disproportionate sexual adverse events in younger versus older subgroups. Rates of decreased libido and erectile dysfunction were comparable across age strata during the 24-week treatment period.
</FAQ>

<FAQ question="Is 0.5 mg the right dutasteride dose for all AGA patient subgroups?">
Based on this trial's dose-response data, 0.5 mg outperformed 0.1 mg and 0.02 mg across all examined subgroups. There is no evidence supporting lower doses for any patient subtype. The 0.5 mg dose should be used regardless of age or baseline severity.
</FAQ>

<FAQ question="How long was the Eun dutasteride trial, and does 24 weeks capture full subgroup effects?">
The trial lasted 24 weeks. AGA treatment typically requires 12-24 months for maximal effect. Subgroup differences at 6 months may underestimate or overestimate long-term patterns. Extension data from the Gubelin Harcha study at 48 weeks confirmed sustained dutasteride superiority overall.
</FAQ>

<FAQ question="Can women use these subgroup findings to guide dutasteride use for hair loss?">
No. The trial enrolled only men, and dutasteride is contraindicated in women of childbearing potential due to teratogenic risk (category X). These subgroup results apply exclusively to male androgenetic alopecia.
</FAQ>

<FAQ question="Should clinicians check DHT levels before prescribing dutasteride based on this trial?">
The trial did not demonstrate that baseline DHT levels predict hair count response. While dutasteride suppresses serum DHT by over 90%, no validated threshold exists below which the drug is ineffective. Pre-treatment DHT testing is not supported by this evidence.
</FAQ>

<FAQ question="Does this trial support switching from finasteride to dutasteride?">
Yes, particularly for younger patients with stage IIIv-IV hair loss. The subgroup data show that dutasteride's superiority over finasteride is most pronounced in patients with earlier disease and younger age, making these the best candidates for a therapeutic switch.
</FAQ>
</FAQAccordion>

<References>
1. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258. https://pubmed.ncbi.nlm.nih.gov/20691790/

2. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. https://pubmed.ncbi.nlm.nih.gov/16384751/

3. Gubelin Harcha W, Barboza Martinez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-498. https://pubmed.ncbi.nlm.nih.gov/24411083/

4. Dutasteride (Avodart) prescribing information. GlaxoSmithKline. Revised 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s034lbl.pdf

5. Kinoshita-Ise M, Fukuyama M, Ohyama M. Recent advances in understanding of the etiopathogenesis, diagnosis, and management of androgenetic alopecia. J Dermatol. 2022;49(1):e1-e13. https://pubmed.ncbi.nlm.nih.gov/29178381/
</References>